Maurel M, Howard J, Kissling E, Pozo F, Pérez-Gime. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. Euro Surveill. 2024 Feb;29(8)
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.
See Also:
Latest articles in those days:
- Molecular characterization and genetic analysis of highly pathogenic H5N1 clade 2.3.4.4b in seagulls from Dukan Lake, Iraq 1 days ago
- The sweet side of H5N1 influenza virus infection 1 days ago
- Phosphorylation of PA at serine 225 enhances viral fitness of the highly pathogenic H5N1 avian influenza virus in mice 1 days ago
- Receptor binding, structure, and tissue tropism of cattle-infecting H5N1 avian influenza virus hemagglutinin 1 days ago
- Characterization of novel highly pathogenic avian influenza A(H5N6) clade 2.3.4.4b virus in wild birds, East China, 2024 1 days ago
[Go Top] [Close Window]
